Inflammatory Biomarkers and Disease Activity in Inflammatory Bowel Disease

Conditions

• Crohn Disease
• Inflammatory Bowel Diseases
• Ulcerative Colitis (UC)

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Study Details

This study aims to evaluate the diagnostic accuracy and clinical utility of routine blood-derived inflammatory biomarker ratios in assessing disease activity among adult patients with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Endoscopy is the standard method for evaluating mucosal inflammation in IBD, but it is invasive, costly, and inconvenient for frequent disease monitoring. Non-invasive, inexpensive laboratory markers derived from standard routine blood tests, specifically the C-reactive protein-to-albumin ratio (CAR), platelet-to-albumin ratio (PAR), neutrophil-to-lymphocyte ratio (NLR), fibrinogen-to-albumin ratio (FAR), and hemoglobin-to-CRP ratio (Hb/CRP), have shown potential in reflecting systemic and intestinal inflammation. Participants enrolled in this cross-sectional study will undergo routine clinical disease activity evaluations and standard blood tests. For patients undergoing routine colonoscopy, endoscopic disease activity scores will also be recorded. The primary goal is to determine how accurately these blood-based ratios can differentiate active IBD from disease remission, providing a simple, cost-effective tool for regular patient monitoring.

Key Dates

First listed

Aug 26, 2026

Start date

Sep 30, 2026

Status verified

Aug 2026

Primary completion

Sep 30, 2027

Completion

Oct 31, 2027

Study Design

Enrollment

120 participants (estimated)

Arms

• Arm: IBD Patients
  Adult patients aged 18 years or older with an established diagnosis of inflammatory bowel disease (Crohn's disease or ulcerative colitis) undergoing clinical and/or endoscopic disease activity evaluation along with routine laboratory investigations.

Primary Outcome Measure

Area Under the Receiver Operating Characteristic Curve (AUC) of the C-Reactive Protein-to-Albumin Ratio (CAR) [ Time Frame: Day 1 ]

Find similar trials

Related Studies

• The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
  Recruiting · University of Chicago · Chicago, Illinois
• Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
  Recruiting · University of California, San Diego · La Jolla, California
• Improving the Quality of Care for Adults With Inflammatory Bowel Disease
  Enrolling By Invitation · Dartmouth-Hitchcock Medical Center · Los Angeles, California
• CorEvitas Inflammatory Bowel Disease (IBD) Registry
  Enrolling By Invitation · CorEvitas · Waltham, Massachusetts